Blood Infection Testing segmentation by type maps the technological palette that laboratories deploy to detect and quantify pathogens in blood. Conventional automated blood culture systems still dominate volume because they incubate and flag positives with minimal hands-on time, making them the default entry point in mid-tier hospitals. Within this segment, continuous-monitoring instruments (e.g., BacT/ALERT) account for the largest share, while lysis-centrifugation bottles serve niches where fastidious fungi or intracellular bacteria are suspected. Molecular assays—multiplex PCR, T2MR, and digital droplet platforms—are the fastest-expanding category, capturing double-digit growth by compressing time-to-result from days to hours and enabling direct antimicrobial resistance gene detection, a capability that culture cannot match. Immunoassays, mainly procalcitonin and ß-D-glucan kits, occupy a smaller, high-margin slice leveraged for triage and antibiotic stewardship rather than definitive diagnosis. Finally, next-generation sequencing remains nascent but is rapidly migrating from reference labs to core hospital workflows as sequencing costs fall and bioinformatics pipelines standardize, positioning it as the long-term growth engine within the type taxonomy.
